AZ-CAMELBACK-OWNER
One Can Imagine. That philosophy is the driving force of the experienced leadership team that’s responsible for introducing One Camelback, an innovative live-play community that’s taking shape at the hottest intersection in greater Phoenix, according to real estate and growth experts at Urban Land Institute.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200316005151/en/
“Arizona hasn’t seen anything quite like One Camelback – we expect this bold development to set a new benchmark for urban elegant living in the Southwest,” said Dale Phillips, President and Founder of Stellar Residential, the management company for One Camelback. “As one of the most ambitious construction transformations ever undertaken in Phoenix, this boutique, Class A development will deliver a vibrant use of residential space, with soaring and dramatic floor-to-ceiling views of Central Phoenix, modern and functional floorplans, upscale amenities and first-class services – all under one 11-story roof, while aesthetically adding some more glamour and elegance to the Phoenix skyline.”
As the iconic landmark undergoes a complete transformation, One Camelback will blend the finest there is in upscale sophisticated living with a range of exclusive, first-to-market retailers in the heart of Central Phoenix. It will be the first 1-Gigabit community, in Arizona through Cox Communications, which means each and every unit will have 1-Gigabit internet speeds included in the rent.
The 215,245-square-foot glass-ensconced property will include 163 first-class apartment units with exposed ceilings and 10 foot floor to ceiling windows. A selection of 16 different floorplans will be available, featuring upscale studio, 1-, 2-, and 3-bedroom apartments, all designed by Erwin Architecture. Additional exclusive residential amenities include a 6,500 square-foot rooftop terrace with a swimming pool, a swim-in place and endless pool for lap swimming or therapy, cabanas and a spa, as well as a yoga lawn deck and a lounge-style clubhouse. Residents will also have access to a secured underground garage with electric car-charging stations.
Capitalizing on its prime location, One Camelback is in negotiations to bring in highly sought-after, first-to-market upscale retailers to blend in with the historic neighborhood’s assortment of hip restaurants and trendy shops. Only walking distance from popular gourmet and specialty grocer AJ’s Fine Foods, One Camelback is also in close proximity to Uptown Plaza and light-rail transportation. The residences and retail spaces will be moments away from the downtown business core, major sporting event arenas, and the popular nightlife scene, serving residents by offering one of the best transit oriented developments known to the Valley.
With more than 143,000 people working within a 3-mile radius of its centralized location, One Camelback is located at the perfect triangle, connecting downtown Phoenix to the Biltmore area.
In March 2019, the construction efforts began with a glass-raising event to celebrate the start of the substantial transformation, from mortar and concrete to dramatic windows and high ceilings that will deliver soaring, bird’s eye views of Central Phoenix. The demolition of interior structures throughout the building was completed earlier this month, leaving a blank canvas for crews to make the vision for this iconic development come to a reality.
One Camelback is being developed by an affiliate of Sagamore Capital LLC, a Scottsdale-based investment firm, with financing arranged by Walker & Dunlop, and provided by Los Angeles-based ACORE Capital LLC. Katerra is acting as general contractor and a prime supplier for the project.
One Camelback is expected to be complete by 2021. More information is available by visiting OneCamelback.com or @LiveOneCamelback on Instagram.
About One Camelback
Situated at the hottest intersection in greater Phoenix, at the southeast corner of Central Ave. & Camelback Road, One Camelback will set a new standard in redefined upscale urban living. With its iconic glass exterior, extravagant residential units and amenities, first-class services and exclusive retail experiences, the boutique Class A development will deliver a highly desirable live-play lifestyle in a building that is expected to help redefine the Phoenix skyline. For more information about One Camelback, visit OneCamelback.com or @LiveOneCamelback on Instagram.
About Sagamore Capital LLC
One Camelback Owner LLC is an affiliate of Sagamore Capital LLC. In addition to One Camelback, Sagamore Capital and its affiliates currently have under development multifamily rental projects in Spokane, Washington, Brooklyn, New York, Jamaica (Queens), New York and Washington D.C., a student housing project in Pullman, Washington and a 14-unit condominium project in the Nolita area of Manhattan. It has been active in the Phoenix area with the successful acquisition and sale of student housing projects and two multifamily projects. Its affiliates are also investors in land developments located in Buckeye and Surprise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200316005151/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom